N-(imidazo[1,2-a]pyridin-6-ylmethyl)-5-(2'-methoxy-[1,1'-biphenyl]-4-yl)-N-methyl-1,3,4-oxadiazol-2-amine

ID: ALA4859554

PubChem CID: 164613744

Max Phase: Preclinical

Molecular Formula: C24H21N5O2

Molecular Weight: 411.47

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  COc1ccccc1-c1ccc(-c2nnc(N(C)Cc3ccc4nccn4c3)o2)cc1

Standard InChI:  InChI=1S/C24H21N5O2/c1-28(15-17-7-12-22-25-13-14-29(22)16-17)24-27-26-23(31-24)19-10-8-18(9-11-19)20-5-3-4-6-21(20)30-2/h3-14,16H,15H2,1-2H3

Standard InChI Key:  GUZYREPIQDATAM-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 31 35  0  0  0  0  0  0  0  0999 V2000
    1.2836  -12.1258    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9888  -12.5303    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6941  -12.1258    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6941  -11.3086    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2875  -11.3064    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9888  -10.8959    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.8152  -10.1019    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0064  -10.0217    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6804  -10.7661    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.4012  -12.5354    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1095  -12.1279    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.8167  -12.5375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1107  -11.3107    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8997  -13.3502    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.6988  -13.5213    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.1085  -12.8141    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5625  -12.2061    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.9213  -12.7298    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3984  -13.3929    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2105  -13.3090    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5446  -12.5623    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0606  -11.8986    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2502  -11.9858    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.3573  -12.4769    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.8351  -13.1408    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.6471  -13.0559    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.9803  -12.3087    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.4954  -11.6457    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.6851  -11.7340    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.5009  -13.8865    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.9796  -14.5489    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  5  1  1  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  6  1  0
  5  6  1  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9  5  2  0
  3 10  1  0
 10 11  1  0
 11 12  1  0
 11 13  1  0
 12 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 12  1  0
 16 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 18  1  0
 21 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 29 24  1  0
 25 30  1  0
 30 31  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4859554

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 411.47

Molecular Weight (Monoisotopic): 411.1695

AlogP: 4.70

#Rotatable Bonds: 6

Polar Surface Area: 68.69

Molecular Species: NEUTRAL

HBA: 7

HBD: ┄

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): ┄

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 6.32

CX LogP: 3.77

CX LogD: 3.74

Aromatic Rings: 5

Heavy Atoms: 31

QED Weighted: 0.40

Np Likeness Score: -1.35

References

1. McCoull W, Boyd S, Brown MR, Coen M, Collingwood O, Davies NL, Doherty A, Fairley G, Goldberg K, Hardaker E, He G, Hennessy EJ, Hopcroft P, Hodgson G, Jackson A, Jiang X, Karmokar A, Lainé AL, Lindsay N, Mao Y, Markandu R, McMurray L, McLean N, Mooney L, Musgrove H, Nissink JWM, Pflug A, Reddy VP, Rawlins PB, Rivers E, Schimpl M, Smith GF, Tentarelli S, Travers J, Troup RI, Walton J, Wang C, Wilkinson S, Williamson B, Winter-Holt J, Yang D, Zheng Y, Zhu Q, Smith PD..  (2021)  Optimization of an Imidazo[1,2-a]pyridine Series to Afford Highly Selective Type I1/2 Dual Mer/Axl Kinase Inhibitors with In Vivo Efficacy.,  64  (18.0): [PMID:34478292] [10.1021/acs.jmedchem.1c00920]

Source

Source(1):

• Scientific Literature